The price of Codexis Inc. (NASDAQ:CDXS) shares last traded on Wall Street rose 0.23% to $4.27.
Based on available information, 8 analysts follow Codexis Inc. (NASDAQ:CDXS). The consensus rating among analysts is ‘Buy’. As we calculate the median target price by taking the range between a high of $22.00 and a low of $9.00, we find $13.00. Given the previous closing price of $4.26, this indicates a potential upside of 205.16 percent. CDXS stock price is now -22.63% away from the 50-day moving average and -55.07% away from the 200-day moving average. The market capitalization of the company currently stands at $295.74M.
Among analysts, 0 rate the stock a hold while 8 rate it a buy. Brokers who have rated the stock have averaged $14.38 as their price target over the next twelve months.
, while ‘Piper Sandler’ rates the stock as ‘Overweight’.
In other news, NICOLS JOHN J, Director sold 35,714 shares of the company’s stock on Dec 12. The stock was sold for $202,820 at an average price of $5.68. Upon completion of the transaction, the Director now directly owns 863,535 shares in the company, valued at $3.69 million. An SEC document containing details of the transaction can be found on the SEC’s website. On Dec 09, Director NICOLS JOHN J sold 39,785 shares of the business’s stock. A total of $224,996 was realized by selling the stock at an average price of $5.66. This leaves the insider owning 863,535 shares of the company worth $3.69 million. Insiders disposed of 479,228 shares of company stock worth roughly $2.05 million over the past 1 year. A total of 1.40% of the company’s stock is owned by insiders.
There have been several recent changes in the stakes of large investors in CDXS stock. A new stake in Codexis Inc. shares was purchased by JACOBS LEVY EQUITY MANAGEMENT, INC during the first quarter worth $5,669,000. VOLORIDGE INVESTMENT MANAGEMENT, LLC invested $1,249,000 in shares of CDXS during the first quarter. In the first quarter, KNOTT DAVID M JR acquired a new stake in Codexis Inc. valued at approximately $948,000. RENAISSANCE TECHNOLOGIES LLC acquired a new stake in CDXS for approximately $662,000. CANDRIAM S.C.A. purchased a new stake in CDXS valued at around $610,000 in the second quarter. In total, there are 240 active investors with 95.90% ownership of the company’s stock.
A candlestick chart of Codexis Inc. (NASDAQ: CDXS) showed a price of $4.2400 on Wednesday morning. During the past 12 months, Codexis Inc. has had a low of $4.21 and a high of $34.25. As of last week, the company has a debt-to-equity ratio of 0.00, a current ratio of 4.60, and a quick ratio of 4.50. The fifty day moving average price for CDXS is $5.5188 and a two-hundred day moving average price translates $9.5028 for the stock.
The latest earnings results from Codexis Inc. (NASDAQ: CDXS) was released for Jun, 2022. According to the Biotechnology Company, earnings per share came in at -$0.04, beating analysts’ expectations of -$0.13 by 0.09. This compares to $0.03 EPS in the same period last year. The net profit margin was -23.50% and return on equity was -19.60% for CDXS. The company reported revenue of $34.47 million for the quarter, compared to $36.77 million a year earlier. Comparatively to last year’s same quarter, the company’s quarterly revenue fell -6.25 percent. For the current quarter, analysts expect CDXS to generate $30.94M in revenue.
Codexis Inc.(CDXS) Company Profile
Codexis, Inc. discovers, develops, and sells enzymes and other proteins. It offers biocatalyst products and services; intermediate chemicals products that are used for further chemical processing; and Codex biocatalyst panels and kits that enable customers to perform chemistry screening. The company also provides biocatalyst screening and protein engineering services. In addition, it offers CodeEvolver protein engineering technology platform, which helps in developing and delivering biocatalysts that perform chemical transformations and enhance the efficiency and productivity of manufacturing processes. The company’s platform is also used to discover novel biotherapeutic drug candidates for targeted human diseases, as well as for molecular biology and in vitro diagnostic enzymes. It sells its products to pharmaceutical manufacturers through its direct sales and business development force in the United States and Europe. The company was incorporated in 2002 and is headquartered in Redwood City, California.